Goals for Pay for Performance in Hematopoietic Cell Transplantation: A Primer
- PMID: 25889042
- DOI: 10.1016/j.bbmt.2015.04.014
Goals for Pay for Performance in Hematopoietic Cell Transplantation: A Primer
Abstract
Bundled payments for hematopoietic cell transplantation (HCT) have long been accepted by both commercial health insurance providers and transplant centers, effectively outpacing the use of this payment model elsewhere in health care. As with the rest of health care, interest in payment and health delivery reform has created demand for transplant providers to address value by incorporating quality metrics and strategic changes in network design The complexity of evaluating performance in HCT complicates the goal of rewarding providers for better performance and penalizing poor results. We provide an introduction to value-based purchasing and address potential considerations in the adoption of incentives to improve quality of care in HCT.
Keywords: Bundled payments; Hematopoietic cell transplantation; Pay for performance; Value-based purchasing.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients.Biol Blood Marrow Transplant. 2018 Jan;24(1):4-12. doi: 10.1016/j.bbmt.2017.09.012. Epub 2017 Sep 28. Biol Blood Marrow Transplant. 2018. PMID: 28963077
-
Optimal benefits for hematopoietic stem cell transplantation: a consensus opinion.Biol Blood Marrow Transplant. 2014 Nov;20(11):1671-6. doi: 10.1016/j.bbmt.2014.07.007. Epub 2014 Jul 12. Biol Blood Marrow Transplant. 2014. PMID: 25020102
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Performance-based bundled payments: potential benefits and burdens.Minn Med. 2009 Oct;92(10):33-5. Minn Med. 2009. PMID: 19916270
-
Blood and marrow transplantation compensation: perspective in payer and provider relations.Biol Blood Marrow Transplant. 2004 Jul;10(7):427-32. doi: 10.1016/j.bbmt.2004.03.004. Biol Blood Marrow Transplant. 2004. PMID: 15205664 Review.
Cited by
-
Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities.Curr Hematol Malig Rep. 2018 Apr;13(2):125-134. doi: 10.1007/s11899-018-0444-z. Curr Hematol Malig Rep. 2018. PMID: 29484578 Free PMC article. Review.
-
User-Centered Design Groups to Engage Patients and Caregivers with a Personalized Health Information Technology Tool.Biol Blood Marrow Transplant. 2016 Feb;22(2):349-358. doi: 10.1016/j.bbmt.2015.08.032. Epub 2015 Sep 5. Biol Blood Marrow Transplant. 2016. PMID: 26343948 Free PMC article.
-
National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report.Biol Blood Marrow Transplant. 2017 May;23(5):717-725. doi: 10.1016/j.bbmt.2016.09.025. Epub 2016 Oct 3. Biol Blood Marrow Transplant. 2017. PMID: 27713091 Free PMC article. Review.
-
Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities.Biol Blood Marrow Transplant. 2016 Oct;22(10):1738-1746. doi: 10.1016/j.bbmt.2016.05.005. Epub 2016 May 14. Biol Blood Marrow Transplant. 2016. PMID: 27184624 Free PMC article. Review.
-
Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access.Stem Cells Transl Med. 2017 Aug;6(8):1723-1729. doi: 10.1002/sctm.16-0487. Stem Cells Transl Med. 2017. PMID: 28749065 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials